A patient with agranulocytosis following the discontinuation of methimazole treatment for 4 months: A case report

Agranulocytosis is a rare and serious adverse effect of antithyroid drugs (ATD), in particular methimazole (MMI), and usually develops within 3 months following the start of uninterrupted ATD treatment. Agranulocytosis may also develop for the first time following interruption and subsequent resumpt...

Descripción completa

Detalles Bibliográficos
Autores principales: BAI, XIAO-SU, LIU, JING-HAI, XIAO, SHAO-MEI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113532/
https://www.ncbi.nlm.nih.gov/pubmed/25120607
http://dx.doi.org/10.3892/etm.2014.1817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113532/
https://www.ncbi.nlm.nih.gov/pubmed/25120607
http://dx.doi.org/10.3892/etm.2014.1817

Ejemplares similares